Nanox to Introduce New Nanox.ARC Procedures, Highlight Nanox.AI Software Solutions at 2021 Radiology Society of North America Annual Meeting
NANO-X IMAGING LTD (NASDAQ: NNOX) announced its participation in the 2021 Radiology Society of North America (RSNA) Annual Meeting from Nov. 28 to Dec. 2. Key highlights include the debut of the Nanox.ARC procedures at their virtual booth and a showcase of AI-enabled medical imaging solutions at booth 4949. A virtual tour from Shamir Medical Center will occur on Dec. 1 at 10:30 am CST. These advancements aim to enhance affordability and accessibility in medical imaging, aligning with their goal of improving early detection services.
- Introduction of Nanox.ARC procedures at RSNA, enhancing product visibility.
- Showcasing AI-enabled imaging solutions, positioning as a leader in innovation.
- Potential for improved affordability in medical imaging services.
- Risks related to integration and realization of benefits from acquisitions.
- Uncertainties surrounding market acceptance of Nanox.ARC and pay-per-scan model.
- Regulatory compliance challenges and potential delays in technology development.
First-ever unveiling of Nanox.ARC new features and procedures
Nanox.AI to feature AI-enabled medical imaging software solutions
- Nanox will present leading Nanox.ARC procedures for the first time, at the company’s virtual booth. Nanox.ARC is a multi-source, digital tomosynthesis system. A link to the virtual booth will be available on Nanox’s website and the RSNA conference website prior to the meeting.
-
Nanox.AI will host an on-site booth (booth 4949, South
Hall Level 3) where the Company will showcase its AI-enabled medical imaging software population health solutions, as part of its value-based care offerings for healthcare systems and payers, expected to set a new standard in the medical technology sector. -
Nanox will present a virtual tour of Nanox.ARC in a clinical setting, broadcast from
Shamir Medical Center (Assaf Harofeh ), a leading government hospital inIsrael with advanced diagnostic imaging capabilities. The event will be broadcast onWednesday, Dec. 1 , at10:30 am CST and can be viewed at Nanox’s virtual booth.
About Nanox
Nanox, founded by the serial entrepreneur
About Nanox.AI
Using patient imaging data already available to the healthcare system, proprietary algorithms highlight early, previously undetected signs of common chronic diseases. The newly discovered findings can then initiate further medical assessment to establish individual preventative care pathways for patients.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of the acquisitions, and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (1) the inability to successfully integrate the acquired companies’ business, (2) the inability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees, (3) costs related to the acquisitions and/or unknown or inestimable liabilities, (4) changes in applicable laws or regulations that impact the operations of the acquired companies, (5) the failure to meet projected technology development targets, (6) the failure of the acquired companies to effectively scale end-to-end medical imaging solutions worldwide, (7) changes in global, political, economic, business, competitive, market and regulatory forces, and (8) (i) Nanox’s ability to complete development of the Nanox.Arc ; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; (v) the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; (vi) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and (vii) Nanox's ability to conduct business globally, among other things.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended
Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this report to conform these statements to actual results or to changes in the Company's expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005743/en/
Media Contact:
ICR Westwicke
NanoxPR@icrinc.com
Source:
FAQ
What is NNOX's announcement about the RSNA Annual Meeting?
When will the virtual tour of Nanox.ARC take place?
What are Nanox.AI's features presented at the RSNA Meeting?